Design of potent poxvirus inhibitors of the heterodimeric processivity factor required for viral replication

Journal of Medicinal Chemistry

Volumn 56, Issue 8, 2013, Pages 3235-3246

  Nuth, Manunya ^a   Guan, Hancheng ^a   Zhukovskaya, Natalia ^a   Saw, Yih Ling ^a   Ricciardi, Robert P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 [(3,5 DICHLOROPHENYL)THIO] 6 METHYL 1H INDOL 2 YL]ACETAMIDE; 3 [(4 CHLOROPHENYL)THIO] 6 METHYL 1H INDOLE 2 CARBOXYLIC ACID; 3 [3 [(3,5 DICHLOROPHENYL)THIO] 6 METHYL 1H INDOL 2 YL] N HEXYLPROPANAMIDE; 3 [3 [(3,5 DICHLOROPHENYL)THIO] 6 METHYL 1H INDOL 2 YL]PROPANAMIDE; 3 [3 [(3,5 DICHLOROPHENYL)THIO] 6 METHYL 1H INDOL 2 YL]PROPANOIC ACID; 4 [3 [(3,5 DICHLOROPHENYL)THIO] 6 METHYL 1H INDOL 2 YL]BUTANAMIDE; ANTIVIRUS AGENT; BROXURIDINE; HETERODIMER; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL CELL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CYTOPLASM; DNA SYNTHESIS; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HYDROGEN BOND; IC 50; LIPOPHILICITY; NONHUMAN; POXVIRUS; POXVIRUS INFECTION; PROCESS OPTIMIZATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG DESIGN; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; STRUCTURE-ACTIVITY RELATIONSHIP; VACCINIA; VACCINIA VIRUS; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 84876824179     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301735k     Document Type: Article

References (37)

1. Longini, I. M., Jr.; Halloran, M. E.; Nizam, A.; Yang, Y.; Xu, S.; Burke, D. S.; Cummings, D. A.; Epstein, J. M. Containing a large bioterrorist smallpox attack: a computer simulation approach Int. J. Infect. Dis. 2007, 11, 98-108
2. Kong, X. P.; Onrust, R.; O'Donnell, M.; Kuriyan, J. Three-dimensional structure of the beta subunit of E. coli DNA polymerase III holoenzyme: a sliding DNA clamp Cell 1992, 69, 425-437
3. Krishna, T. S.; Kong, X. P.; Gary, S.; Burgers, P. M.; Kuriyan, J. Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA Cell 1994, 79, 1233-1243
4. Ellison, V.; Stillman, B. Opening of the clamp: an intimate view of an ATP-driven biological machine Cell 2001, 106, 655-660
5. Gottlieb, J.; Marcy, A. I.; Coen, D. M.; Challberg, M. D. The herpes simplex virus type 1 UL42 gene product: a subunit of DNA polymerase that functions to increase processivity J. Virol. 1990, 64, 5976-5987
6. Kiehl, A.; Dorsky, D. I. Cooperation of EBV DNA polymerase and EA-D(BMRF1) in vitro and colocalization in nuclei of infected cells Virology 1991, 184, 330-340
7. Tsurumi, T.; Daikoku, T.; Kurachi, R.; Nishiyama, Y. Functional interaction between Epstein-Barr virus DNA polymerase catalytic subunit and its accessory subunit in vitro J. Virol. 1993, 67, 7648-7653
8. Weiland, K. L.; Oien, N. L.; Homa, F.; Wathen, M. W. Functional analysis of human cytomegalovirus polymerase accessory protein Virus Res. 1994, 34, 191-206
9. Agulnick, A. D.; Thompson, J. R.; Iyengar, S.; Pearson, G.; Ablashi, D.; Ricciardi, R. P. Identification of a DNA-binding protein of human herpesvirus 6, a putative DNA polymerase stimulatory factor J. Gen. Virol. 1993, 74 (Pt 6) 1003-1009
10. Lin, K.; Ricciardi, R. P. The 41 kDa protein of human herpesvirus 6 specifically binds to viral DNA polymerase and greatly increases DNA synthesis Virology 1998, 250, 210-219
11. Lin, K.; Dai, C. Y.; Ricciardi, R. P. Cloning and functional analysis of Kaposi's sarcoma-associated herpesvirus DNA polymerase and its processivity factor J. Virol. 1998, 72, 6228-6232
12. Klemperer, N.; McDonald, W.; Boyle, K.; Unger, B.; Traktman, P. The A20R protein is a stoichiometric component of the processive form of vaccinia virus DNA polymerase J. Virol. 2001, 75, 12298-12307
13. Stanitsa, E. S.; Arps, L.; Traktman, P. Vaccinia virus uracil DNA glycosylase interacts with the A20 protein to form a heterodimeric processivity factor for the viral DNA polymerase J. Biol. Chem. 2006, 281, 3439-3451
14. Druck Shudofsky, A. M.; Silverman, J. E. Y.; Chattopadhyay, D.; Ricciardi, R. P. Vaccinia D4 mutants defective in processive DNA synthesis retain A20 and DNA binding J. Virol. 2010, 84, 12325-12335
15. Boyle, K. A.; Stanitsa, E. S.; Greseth, M. D.; Lindgren, J. K.; Traktman, P. Evaluation of the role of the vaccinia virus uracil DNA glycosylase and A20 proteins as intrinsic components of the DNA polymerase holoenzyme J. Biol. Chem. 2011, 286, 24702-24713
16. Nuth, M.; Huang, L.; Saw, Y. L.; Schormann, N.; Chattopadhyay, D.; Ricciardi, R. P. Identification of inhibitors that block vaccinia virus infection by targeting the DNA synthesis processivity factor D4 J. Med. Chem. 2011, 54, 3260-3267
17. Schormann, N.; Sommers, C. I.; Prichard, M. N.; Keith, K. A.; Noah, J. W.; Nuth, M.; Ricciardi, R. P.; Chattopadhyay, D. Identification of protein-protein interaction inhibitors targeting vaccinia virus processivity factor for development of antiviral agents Antimicrob. Agents Chemother. 2011, 55, 5054-5062
18. Sele, C.; Gabel, F.; Gutsche, I.; Ivanov, I.; Burmeister, W. P.; Iseni, F.; Tarbouriech, N. Low-resolution structure of vaccinia virus DNA replication machinery J. Virol. 2013, 87, 1679-1689
19. Bonneau, R.; Strauss, C. E.; Rohl, C. A.; Chivian, D.; Bradley, P.; Malmstrom, L.; Robertson, T.; Baker, D. De novo prediction of three-dimensional structures for major protein families J. Mol. Biol. 2002, 322, 65-78
20. Bonneau, R.; Strauss, C. E.; Baker, D. Improving the performance of Rosetta using multiple sequence alignment information and global measures of hydrophobic core formation Proteins 2001, 43, 1-11
21. Simons, K. T.; Ruczinski, I.; Kooperberg, C.; Fox, B. A.; Bystroff, C.; Baker, D. Improved recognition of native-like protein structures using a combination of sequence-dependent and sequence-independent features of proteins Proteins 1999, 34, 82-95
22. Ishii, K.; Moss, B. Mapping interaction sites of the A20R protein component of the vaccinia virus DNA replication complex Virology 2002, 303, 232-239
23. Schormann, N.; Grigorian, A.; Samal, A.; Krishnan, R.; DeLucas, L.; Chattopadhyay, D. Crystal structure of vaccinia virus uracil-DNA glycosylase reveals dimeric assembly BMC Struct. Biol. 2007, 7, 45
24. Brenke, R.; Kozakov, D.; Chuang, G. Y.; Beglov, D.; Hall, D.; Landon, M. R.; Mattos, C.; Vajda, S. Fragment-based identification of druggable "hot spots" of proteins using Fourier domain correlation techniques Bioinformatics 2009, 25, 621-627
25. Bisht, H.; Weisberg, A. S.; Moss, B. Vaccinia virus L1 protein is required for cell entry and membrane fusion J. Virol. 2008, 82, 8687-8694
26. Chang, H. W.; Watson, J. C.; Jacobs, B. L. The E3l Gene of Vaccinia Virus Encodes an Inhibitor of the Interferon-Induced, Double-Stranded RNA-Dependent Protein-Kinase Proc. Natl. Acad. Sci. U. S. A. 1992, 89, 4825-4829
27. Maa, J. S.; Esteban, M. Structural and Functional-Studies of a 39,000-Mr-Immunodominant Protein of Vaccinia Virus J. Virol. 1987, 61, 3910-3919
28. Risco, C.; Rodriguez, J. R.; Demkowicz, W.; Heljasvaara, R.; Carrascosa, J. L.; Esteban, M.; Rodriguez, D. The vaccinia virus 39 kDa protein forms a stable complex with the p4a/4a major core protein early in morphogenesis Virology 1999, 265, 375-386
29. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nature Rev. Drug Discovery 2007, 6, 881-890
30. Blasco, R.; Moss, B. Extracellular Vaccinia Virus Formation and Cell-to-Cell Virus Transmission Are Prevented by Deletion of the Gene Encoding the 37000 Dalton Outer Envelope Protein J. Virol. 1991, 65, 5910-5920
31. Yang, G.; Pevear, D. C.; Davies, M. H.; Collett, M. S.; Bailey, T.; Rippen, S.; Barone, L.; Burns, C.; Rhodes, G.; Tohan, S.; Huggins, J. W.; Baker, R. O.; Buller, R. L. M.; Touchette, E.; Waller, K.; Schriewer, J.; Neyts, J.; DeClercq, E.; Jones, K.; Hruby, D.; Jordan, R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge J. Virol. 2005, 79, 13139-13149
32. Duraffour, S.; Snoeck, R.; de Vos, R.; van den Oord, J. J.; Crance, J. M.; Garin, D.; Hruby, D. E.; Jordan, R.; De Clercq, E.; Andrei, G. Activity of the anti-orthopoxvirus compound ST-246 against vaccinia, cowpox, and camelpox viruses in cell monolayers and organotypic raft cultures Antivir. Ther. (London) 2007, 12, 1205-1216
33. Smith, S. K.; Olson, V. A.; Karem, K. L.; Jordan, R.; Hruby, D. E.; Damon, I. K. In Vitro Efficacy of ST246 against Smallpox and Monkeypox Antimicrob. Agents Chemother. 2009, 53, 1007-1012
34. Quenelle, D. C.; Collins, D. J.; Kern, E. R. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir Antiviral Res. 2004, 63, 33-40
35. Quenelle, D. C.; Collins, D. J.; Wan, W. B.; Beadle, J. R.; Hostetler, K. Y.; Kern, E. R. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir Antimicrob. Agents Chemother. 2004, 48, 404-412
36. Abagyan, R.; Totrov, M.; Kuznetsov, D. Icm-A New Method for Protein Modeling and Design-Applications to Docking and Structure Prediction from the Distorted Native Conformation J. Comput. Chem. 1994, 15, 488-506
37. Pettersen, E. F.; Goddard, T. D.; Huang, C. C.; Couch, G. S.; Greenblatt, D. M.; Meng, E. C.; Ferrin, T. E. UCSF Chimera-a visualization system for exploratory research and analysis J. Comput. Chem. 2004, 25, 1605-1612